| Name | Title | Contact Details |
|---|
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
FLX Bio, Inc. is a biotechnology company focused on the discovery and development of novel therapies that will improve and prolong the lives of people with cancer. The company is targeting key cancer pathways with its clinical-stage program, FLX925, and building a pipeline of immuno-oncology oral medicines designed to activate a patient`s own immune system to eradicate cancer.
Roche NimbleGen, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Labs-Now is a Garrett Park, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CHUL Research Center is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.